Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill: a Multicenter Mixed-methods Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04755777

Enrollment

138

Registered

2021-02-16

Start date

2020-10-22

Completion date

2022-12-31

Last updated

2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Sepsis

Keywords

pharmacokinetics, therapeutic drug monitoring, mixed methods, implementation science, beta-lactam antibiotic

Brief summary

The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Providers involved with beta-lactam TDM for critically ill patients

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Frequency of drug level testing recommended	Baseline	Indication of how many critically ill patients treated with beta-lactams should receive TDM.
Nature of drug level testing recommended	Baseline	Indication of which types of critically ill patients treated with beta-lactams should receive TDM

Secondary

Measure	Time frame	Description
Determinants of beta-lactam TDM implementation	Baseline	List of factors associated with successful beta-lactam TDM implementation

Countries

Australia, United States

Outcome results